Skip to Content

Amyloid antibodies as future treatment for early Alzheimer’s disease?

More antibodies targeting amyloid have been developed, and one of the raising questions is if they are usable in treating early Alzheimer’s disease. In this MEDtalk, Consultant Neurologist Kristian Steen Frederiksen presents studies investigating the efficacy and safety of the drug lecanemab.

Kristian Steen Frederiksen

Få adgang

Hvis du er læge, sygeplejerske eller anden sundhedsprofessionel kan du få adgang til hele artiklen ved at oprette en profil på BestPractice Nordic.

Back to top